Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yitzhak Zimmer

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Molecular Cancer|May 12, 2023
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risksLusine Hovhannisyan, Carsten Riether, Daniel M Aebersold, et al.
Pharmacology & Therapeutics|July 2, 2020
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventionsMichaela Medová, Matúš Medo, Lusine Hovhannisyan, et al.
Biochimica Et Biophysica Acta|August 18, 2009
Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3betaVanessa M Banz, Michaela Medová, Adrian Keogh, et al.
Biomedicines|December 23, 2022
Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy-A Systematic ReviewDaniel H Schanne, Alexander Koch, Olgun Elicin, et al.
Cancers|April 4, 2015
Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approachesLluís Nisa, Daniel Matthias Aebersold, Roland Giger, et al.
Genes & Cancer|July 23, 2011
MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint ArrestMichaela Medová, Daniel Matthias Aebersold, Wieslawa Blank-Liss, et al.
Oncogene|November 25, 2003
Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynxDaniel M Aebersold, Olfert Landt, Sylvie Berthou, et al.
Genes & Cancer|September 29, 2015
Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancerAnne-Christine Piguet, Michaela Medová, Adrian Keogh, et al.
The FEBS Journal|April 18, 2019
Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven modelsMichaela Poliaková, Andrea Felser, Katarzyna Pierzchala, et al.
Molecular Oncology|May 3, 2015
KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cellsDominic Leiser, Michaela Medová, Kei Mikami, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Molecular Cancer|May 12, 2023
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risksLusine Hovhannisyan, Carsten Riether, Daniel M Aebersold, et al.
Pharmacology & Therapeutics|July 2, 2020
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventionsMichaela Medová, Matúš Medo, Lusine Hovhannisyan, et al.
Biochimica Et Biophysica Acta|August 18, 2009
Hsp90 transcriptionally and post-translationally regulates the expression of NDRG1 and maintains the stability of its modifying kinase GSK3betaVanessa M Banz, Michaela Medová, Adrian Keogh, et al.
Biomedicines|December 23, 2022
Prognostic and Predictive Biomarkers in Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy-A Systematic ReviewDaniel H Schanne, Alexander Koch, Olgun Elicin, et al.
Cancers|April 4, 2015
Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approachesLluís Nisa, Daniel Matthias Aebersold, Roland Giger, et al.
Genes & Cancer|July 23, 2011
MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint ArrestMichaela Medová, Daniel Matthias Aebersold, Wieslawa Blank-Liss, et al.
Oncogene|November 25, 2003
Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynxDaniel M Aebersold, Olfert Landt, Sylvie Berthou, et al.
Genes & Cancer|September 29, 2015
Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancerAnne-Christine Piguet, Michaela Medová, Adrian Keogh, et al.
The FEBS Journal|April 18, 2019
Metabolomics reveals tepotinib-related mitochondrial dysfunction in MET-activating mutations-driven modelsMichaela Poliaková, Andrea Felser, Katarzyna Pierzchala, et al.
Molecular Oncology|May 3, 2015
KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cellsDominic Leiser, Michaela Medová, Kei Mikami, et al.
Pageof 5